Literature DB >> 446506

Histological grading of transitional cell tumours of the bladder. Value of histological grading (WHO) in prognosis.

Y Collan, J Mäkinen, A Heikkinen.   

Abstract

Mortality among 139 patients with transitional cell tumour of the bladder was studied. Tumours were reevaluated according to the grading system recommended by WHO. The absolute 5-year survival of histologically benign papilloma cases was 68%, of grade I carcinoma cases 64%, of grade II carcinoma cases 42% and of grade III carcinoma patients 34%. Clinical staging (UICC), however, would have been more effective than histological grading (WHO) for prognostic purposes. 3 of the 14 patients with histologically benign papilloma in this study developed grade I carcinoma during follow-up periods of between 4.5 and 24 years. Following radical treatment all recurrences were papillomas. The study suggests that histological grading should be used to complement clinical staging in prognosis and that with half-yearly check-ups and elimination of any tumours thus detected, patients with papilloma rarely develop carcinomas of higher grade than grade I.

Entities:  

Mesh:

Year:  1979        PMID: 446506     DOI: 10.1159/000473141

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  3 in total

1.  Tissue polypeptide antigen (TPA), some cytokeratins and epithelial membrane antigen (EMA) in normal, inflamed and malignant urothelium.

Authors:  B E Carbin; V P Collins; P Ekman
Journal:  Urol Res       Date:  1987

2.  The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification.

Authors:  J C Angulo; J I Lopez; N Flores; J D Toledo
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Prognostic factors in WHO grade 2 transitional-cell bladder cancer (TCC); a novel two-grade classification system for TCC based on mitotic index.

Authors:  P K Lipponen; M J Eskelinen; K Jauhiainen; E Harju; P Terho; H Haapasalo
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.